An observational study in Pregnancy, IUGR and Preeclampsia, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by University of Colorado, Denver · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies in Pre-Eclampsia with a site in United States — 62 open to participants now, 78 under way, 6 of them phase 3. Pre-Eclampsia · United States.
Among the 230 studies in Pre-Eclampsia with a site in United States, this one is the 45th largest by planned enrollment of the 69 observational ones that give a count, is one of 11 that started in 2016, is one of 69 observational ones, reaches primary completion later than 22 of the 77 other live ones, and was the 61st registered.
918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
Browse Pre-Eclampsia studies →62 of the 230 studies in Pre-Eclampsia with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–50 · Women only
University of California, Irvine · Sites in United States
Ages 18+ · Women only
University of Alabama at Birmingham · Sites in United States
Ages 16–56 · Women only
Texas Southern University · Sites in United States
Ages 18–45 · Women only
Medicines360 · Sites in United States
Ages 18–99 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 24 · Phase 3 15 · Phase 4 31
First in 2000; this study’s year is marked. 11 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 84 is below the median of 165 across 397 observational studies indexed under Pre-Eclampsia.
Median enrollment 89 across the 161 interventional studies, 125 across the 69 observational. Of the 126 that completed or were terminated, 54 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 230 have an industry lead sponsor. The 10 most frequent:
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
University of Colorado, Denver has 5 studies filed under Pre-Eclampsia — fewer than ten, so there is no comparison to draw.
26 of the studies in Pre-Eclampsia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07222852Phase 3Women and Infants Hospital of Rhode IslandCardiovascular Protection After Preeclampsia With Enalapril | 2027-10-15 |
| NCT07356518Wake Forest University Health SciencesTelehealth and Remote Blood Pressure | 2026-12 |
| NCT05676476University of Alabama at BirminghamThe ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy. | 2026-12 |
| NCT05924971MemorialCare Health SystemAspirin for Postpartum Patients With Preeclampsia | 2026-12 |
| NCT06523569Northwestern UniversityMobile Health Interventions to Prevent Heart Disease After Hypertensive Disorders of Pregnancy | 2026-12-01 |
Add all 26 to your calendar (.ics) → With an account.
Among the 230 studies in Pre-Eclampsia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pregnancy elicits adaptive changes in uteroplacental blood flow, which are altered at high altitude and may contribute to the observed 3-fold increase in intrauterine growth restriction (IUGR) and preeclampsia (PreE). The investigators propose to collect myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA). If altered MA vasoreactivity is found, further studies may be able to link these changes to the increased rates of PreE and IUGR at altitude and contribute to the understanding of these two disorders.
The Investigators will determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries. This will be novel information regarding pregnancy at altitude and of significance not just for women and families in Colorado, but also at high-altitude locations throughout the world. If altered MA vasoreactivity is found, further studies may be able to link these changes to the increased rates of PreE and IUGR at altitude and contribute to the understanding of these two disorders.
The Investigators will also determine whether the chronic hypoxia of high altitude alters DNA methylation patterns and expression of key genes involved in metabolic homeostasis in maternal, placental and fetal cells and, in turn, the relationship of these changes to fetal growth and maternal well-being.
Women scheduled for cesarean delivery at University of Colorado Hospital (Denver, 1600 m) and St. Anthony's Summit Medical Center (Summit County, 3000 m) will be identified. In order to avoid any possible confounding effects of labor or prematurity, only women with elective cesarean deliveries will be approached for enrollment (cesarean delivery at a prescheduled time without any labor, typically at 39 weeks gestation).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Collection of myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
Procedure: Collection of myometrial, cord blood, and placental tissue samples
Collection of myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
Procedure: Collection of myometrial, cord blood, and placental tissue samples
We propose to collect myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
Changes in Myometrial artery dimensions
Myometrial artery dimensions as quantified by immunohistochemistry or other staining techniques, and results of studies of isolated myometrial artery studies in which vasoconstrictor and vasodilator responses to pharmacological agonists are measured using absolute values and the percent maximal contraction to potassium chloride.
Time frame: Up to 1 year
The record gives a start of Jan 2016, a primary completion of Dec 2026 and a completion of Dec 2026. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver →